Skip Navigation
Department of Health and Human Services www.hhs.gov
 
This website is iPhone friendly.

This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.

Evidence-Based Simulations in Practice: Treatment Strategies for Women with Coronary Artery Disease (CAD)

To Receive a Certificate for This Activity:

Course Image
  1. 1. Read the Program Overview on this page.
  2. 2. Review the Faculty Biographies, Accreditation Statements, and Disclosure tabs.
  3. 3. Access the Activity in full.
  4. 4. Complete the Post-Test & Evaluation.
  5. 5. A printable certificate will be available immediately following the activity.

Program Overview

Activity Description

In 2012, the Agency for Healthcare Research and Quality (AHRQ) released a comparative effectiveness review of published studies to assess clinical and safety outcomes, and modifiers of effectiveness of treatment options for women with coronary artery disease. Findings focus on women who present with STEMI, NSTEMI/unstable angina, or chronic stable angina. This interactive video visually presents the evidence from the systematic review findings. Scientific animations provide vivid anatomical reviews of CAD for the learner, and participant polling with feedback engages the learner at several levels. Learners are able to choose patient case studies to apply learning to practice, and are prompted to participate in case-based clinical decisionmaking as supported by the evidence derived from AHRQ's comparative effectiveness review.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify available treatment options for coronary artery disease, specifically for women presenting with STEMI, UA/NSTEMI, or chronic angina
  • Assess the effectiveness of treatment strategies for coronary artery disease in women, including clinical outcomes, modifiers of effectiveness, and safety outcomes based on different characteristics
  • Apply the AHRQ findings for patient-centered clinical decisions utilizing interactive simulations

Target Audience

This CME activity is designed to meet the educational needs of physicians, nurse practitioners, physician assistants, pharmacists, nurses, case managers, and health education specialists.

Method of Participation

To receive a certificate for this activity, you should:

  • Complete the learner assessment pretest
  • View the entire activity online
  • Complete an online evaluation & post-test
  • Print your certificate online

The estimated time to complete this activity, including review of the materials, is 1.0 hour.

Term of Approval

September 15, 2012 through September 14, 2014. Original release date: September 15, 2012.

Acknowledgement of Support

There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).

Faculty Biographies and Disclosures

Click faculty name to view full biography.

Speaker

Manesh R Patel, MD
Associate Professor of Medicine
Director Interventional Cardiology and Catheterization Labs
Duke University Health System and Duke Clinical Research Institute
Durham, NC

Planner

Carolyn LePage, PhD, ARNP
Assistant Professor
Barry University School of Nursing
Miami Shores, FL

Planner

Michele B Kaufman, PharmD, CGP, RPh
President, PRN Communications Inc.
Editor, Pharmacovigilance Forum, P&T Journal
NYCSHP Secretary
Adjunct Faculty
Touro College of Pharmacy
New York, NY

Planner

Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence
East Veterans Affairs Medical Center
Adjunct Faculty
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Washington, DC

Planner

Wanda F Carter, MPH, CHES
Community Collaboration Manager
Wellpoint, Inc
Adjunct Professor, Axia College (U of Phoenix) Health Care Administration Program
Adjunct Professor, Ashford University Health Care Administration Program
PHPS Alumnus, CDC Scientific Education and Professional Development Program Office
Lawrenceville, GA

Peer Reviewer

Sherman Podolsky, MD
Medical Director
Superior HealthPlan
Former Chairman
Department of Emergency Medicine
Albert Einstein Medical Center
Philadelphia, PA

Peer Reviewer

Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
Adjunct Faculty & Preceptor
Albany College of Pharmacy
Albany, NY

Peer Reviewer

Joyce M Knestrick, PhD, CRNP, FAANP
Online Program Director
Associate Professor Georgetown University
Family Nurse Practitioner at Wheeling Health Right
Wheeling, WV

Peer Reviewer

Kathleen A Jarvis, MS, RN, CCM
Clinical Educator
Alere Healthcare
Fort Lauderdale, FL

Begin Activity

Accreditation/Credit Designation

Physician Credit Designation Statement

A C C M E Logo

PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PRIME® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category I credit for completing this program.

Nurse Practitioner Accreditation Statement

Nurse Practitioner Logo

PRIME Education, Inc (PRIME®) is approved as a provider of Nurse Practitioner Continuing Education by the American Association of Nurse Practitioners. Provider number: 060815. This program is accredited for 1.0 contact hour. Program ID# CER43.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Pharmacist Accreditation StatementA C P E Logo

PRIME® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This curriculum has been approved for 1.0 contact hour (0.1 CEUs) by PRIME®. The Universal Activity Number for this program is 0255-0000-12-042-H01-P. This learning activity is Knowledge-Based.

Nurse Accreditation StatementA N C C Logo

PRIME Education, Inc. (PRIME®) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

PRIME® designates this activity for 1.0 contact hour.

Certified Health Education Specialist Accreditation Statement

Sponsored by PRIME Education, Inc. (PRIME®), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.

This program is designated for Certified Health Education Specialists (CHES) to receive up to 1.0 Category I contact hours in health education.

CHES Provider Number: MEP3774

Begin Activity

Faculty Disclosures

Faculty Name
Advisory Board Consultant Grants / Research Salary / Contractual Supported Promotional Education Stock / Shareholder Other Financial Support
Manesh R Patel, MD
Speaker
Bayer, Genzyme None Johnson & Johnson, Astra Zeneca None None None None
Carolyn LePage, PhD, ARNP
Planner
None None None Barry University None None None
Michele B Kaufman, PharmD, CGP, RPh
Planner
None OrthoMcNeil Janssen None None None None None
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
Planner
Consensus Management None None None None None None
Wanda F Carter, MPH, CHES
Planner
None None None None None None None
Sherman Podolsky, MD
Reviewer
None None None None None None None
Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
Reviewer
None None None None None None None
Joyce M Knestrick, PhD, CRNP, FAANP
Reviewer
None None None None None None None
Kathleen A Jarvis, MS, RN, CCM
Reviewer
None None None None None None None
Chris R Prostko, PhD
Scientific Program Director
NoneNoneNonePRIME®NoneNoneNone
Lynn Goldenberg, RN, BSN
Director of Accreditation & Compliance
NoneNoneNonePRIME®NoneNoneNone

Disclosure Policy

PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.

Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.

Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.

Accessibility

PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.

Begin Activity

Pretest

To access the activity, please complete this brief Pretest.

  • Returning user? Login Here!
  1. Before accessing this educational activity, were you aware of the AHRQ-supported comparative effectiveness research on treatment strategies for women with coronary artery disease (CAD)?

  2. Which of the following statements is true regarding coronary artery disease in women and men?

  3. Which of the following treatment options can be considered in women diagnosed with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI)?

  4. How would you describe your current level of confidence in applying comparative effectiveness research on treatment strategies for women with CAD?

  5. How valuable is comparative effectiveness research on treatment strategies for women with CAD in making patient-centered treatment and management decisions?

  6. If you had a clinician summary/consumer summary on treatment strategies for women with CAD, what would you most likely do?

  7. Mrs. G is a 68-year-old Caucasian woman that arrives to the emergency room complaining of acute pain in her chest, radiating to her left shoulder and jaw while watching TV at home. The physician on call performs an immediate electrocardiography which reveals ST-elevation with q-waves. Which of the following statements from the AHRQ review regarding the treatment options for women presenting with CAD is/are correct and most appropriate when deciding available treatment options to treat and manage Mrs. G's condition?

Post-Test & Evaluation

You must access the activity before receiving credit!